Evaluation of a New Molecular Point-of-Care-Testing (POCT) System to Shorten Antibiotic Treatment Duration in Hospitalized Patients with Lower Respiratory Tract Infections: A Randomized Clinical Trial

2019 ◽  
Author(s):  
Shengchen Duan ◽  
Xiaoying Gu ◽  
Guohui Fan ◽  
Ruihua Sun ◽  
Yeming Wang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Respiratory Tract ◽  
Treatment Duration ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Point Of Care ◽  
Point Of Care Testing ◽  
Lower Respiratory Tract Infections ◽  
Tract Infections ◽  
Antibiotic Treatment Duration

Prospective Clinical Trial on the Efficacy of Amoxycillin Administered Twice or Four Times Daily in Children with Respiratory Tract Infections

1981 ◽  
Vol 9 (4) ◽  
pp. 274-276 ◽  
Author(s):  
F D Daschner ◽  
U Behre ◽  
A Dalhoff
Keyword(s):  
Clinical Trial ◽  
Body Weight ◽  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Lower Respiratory Tract Infections ◽  
Duration Of Therapy ◽  
Daily Dose ◽  
Tract Infections ◽  
To Receive

Thirty-four children with upper or lower respiratory tract infections were randomly allocated to receive either a twice daily or four times daily dose of 50 mg amoxycillin/kg body-weight/day. Mean duration of therapy was identical in both groups. Peak and trough antibiotic concentrations were determined. Eradication of bacteria, clinical improvement and side-effects were comparable in both groups.

scholarly journals The Basics and the Advancements in Diagnosis of Bacterial Lower Respiratory Tract Infections

Diagnostics ◽  
2019 ◽  
Vol 9 (2) ◽  
pp. 37 ◽  
Author(s):  
Stephanie Noviello ◽  
David Huang
Keyword(s):  
Respiratory Tract ◽  
Cause Of Death ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Point Of Care ◽  
Patient Treatment ◽  
Resistant Bacteria ◽  
Lower Respiratory Tract Infections ◽  
Reactive Protein ◽  
Tract Infections

Lower respiratory tract infections (LRTIs) are the leading infectious cause of death and the sixth-leading cause of death overall worldwide. Streptococcus pneumoniae, with more than 90 serotypes, remains the most common identified cause of community-acquired acute bacterial pneumonia. Antibiotics treat LRTIs with a bacterial etiology. With the potential for antibiotic-resistant bacteria, defining the etiology of the LRTI is imperative for appropriate patient treatment. C-reactive protein and procalcitonin are point-of-care tests that may differentiate bacterial versus viral etiologies of LRTIs. Major advancements are currently advancing the ability to make rapid diagnoses and identification of the bacterial etiology of LRTIs, which will continue to support antimicrobial stewardship, and is the focus of this review.

Sign in / Sign up

Export Citation Format

Share Document